References

Unresolved reference

1996 · External reference

Rabdoviridae: the viruses and their replication

1996 · External reference

Picornaviridae: the viruses and their replication

1996 · External reference

Paramyxoviridae: the viruses and their replication

1996 · External reference

Herpes simplex viruses and their replication

1996 · External reference

Adenoviridae: the viruses and their replication

1996 · External reference

A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses

10.1093/emboj/19.5.902 · 2000 · External reference

The S4 genome segment of baboon reovirus is bicistronic and encodes a novel fusion-associated small transmembrane protein

10.1128/jvi.76.5.2131-2140.2002 · 2002 · External reference

Reptilian reovirus: a new fusogenic orthoreovirus species

10.1016/j.virol.2003.10.025 · 2004 · External reference

Extensive sequence divergence and phylogenetic relationships between the fusogenic and nonfusogenic orthoreoviruses: a species proposal

10.1006/viro.1999.9832 · 1999 · External reference

To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control

10.1038/sj.onc.1209053 · 2005 · External reference

History of oncolytic viruses: genesis to genetic engineering

10.1038/sj.mt.6300108 · 2007 · External reference

Oncolytic viruses in cancer therapy

10.1016/j.canlet.2007.02.002 · 2007 · External reference

Getting oncolytic virus therapies off the ground

10.1016/s1535-6108(03)00170-3 · 2003 · External reference

The influence of complicating diseases upon leukemia

10.1097/00000441-190412740-00001 · 1996 · External reference

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

10.1038/ncponc0736 · 2007 · External reference

Regression of Burkitt's lymphoma in association with measles infection

10.1016/s0140-6736(71)92086-1 · 1971 · External reference

Viruses in the treatment of cancer

10.1016/s0140-6736(71)92788-7 · 1971 · External reference

Studies on the use of viruses in the treatment of carcinoma of the cervix

10.1002/1097-0142(195611/12)9:6<1211::aid-cncr2820090624>3.0.co;2-7 · 1956 · External reference

Treatment of human cancer with mumps virus

10.1002/1097-0142(197412)34:6<1907::aid-cncr2820340609>3.0.co;2-4 · 1974 · External reference

Present status of oncolytic virus studies

10.1111/j.2164-0947.1960.tb00739.x · 1960 · External reference

Recent progress in the battle between oncolytic viruses and tumours

10.1038/nrc1750 · 2005 · External reference

Naturally oncolytic viruses

2006 · External reference

RNA viruses as virotherapy agents

10.1038/sj.cgt.7700535 · 2002 · External reference

Viruses as anticancer drugs

10.1016/j.tips.2007.05.005 · 2007 · External reference

Progressive development of viral therapy of human cancers-a personal narrative account

2005 · External reference

Unresolved reference

External reference

An adenovirus mutant that replicates selectively in p53-deficient human tumour cells

10.1126/science.274.5286.373 · 1996 · External reference

Exploiting tumour-specific defects in the interferon pathway with a previously unknown oncolytic virus

10.1038/77558 · 2000 · External reference

Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB

10.1093/emboj/16.2.406 · 1997 · External reference

TIR, CARD and PYRIN: three domains for an antimicrobial triad

10.1038/sj.cdd.4401890 · 2006 · External reference

Antiviral innate immunity pathways

10.1038/sj.cr.7310019 · 2006 · External reference

TLR3 in antiviral immunity: key player or bystander?

10.1016/j.it.2005.07.002 · 2005 · External reference

VSV-tumour selective replication and protein translation

10.1038/sj.onc.1209042 · 2005 · External reference

Reoviruses and the interferon system

1998 · External reference

The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon

10.1128/jvi.65.9.5102-5104.1991 · 1991 · External reference

Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins

10.1128/jvi.72.2.1314-1323.1998 · 1998 · External reference

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

10.1016/s1535-6108(03)00241-1 · 2003 · External reference

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

10.1126/science.275.5304.1320 · 1997 · External reference

Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy

10.1089/10430340460745829 · 2004 · External reference

Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells

10.1002/jgm.543 · 2004 · External reference

Cancer genes and the pathways they control

10.1038/nm1087 · 2004 · External reference

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumour selectivity

10.1016/j.ccr.2004.11.012 · 2004 · External reference

Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene

1994 · External reference

The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34

10.1128/jvi.71.12.9442-9449.1997 · 1997 · External reference

Development of transcriptionally regulated oncolytic adenoviruses

10.1038/sj.onc.1209048 · 2005 · External reference

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer

10.1016/j.ymthe.2006.02.011 · 2006 · External reference

Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumours

10.2174/156652305774964659 · 2005 · External reference

Viruses—seeking and destroying the tumour program

10.1038/sj.onc.1209047 · 2005 · External reference

The adenovirus death protein (E3–11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells

10.1128/jvi.70.4.2296-2306.1996 · 1996 · External reference

The early region 4 orf4 protein of human adenovirus type 5 induces p53-independent cell death by apoptosis

10.1128/jvi.72.9.7144-7153.1998 · 1998 · External reference

Newcastle disease virus as an antineoplastic agent: induction of tumour necrosis factor-alpha and augmentation of its cytotoxicity

10.1093/jnci/80.16.1305 · 1988 · External reference

The “bystander effect”: tumour regression when a fraction of the tumour mass is genetically modified

1993 · External reference

Oncolytic viruses: what's next?

10.2174/156800907780058844 · 2007 · External reference

Oncolytic viral therapies - the clinical experience

10.1038/sj.onc.1209037 · 2005 · External reference

Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy

1986 · External reference

VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumour growth

10.1038/sj.mt.6300023 · 2007 · External reference

Cancer: mixing cocktails

10.1038/449993a · 2007 · External reference

Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer

2003 · External reference

ReVOLT: radiation-enhanced viral oncolytic therapy

10.1016/j.ijrobp.2006.06.034 · 2006 · External reference

Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression

10.1089/hum.2007.081 · 2007 · External reference

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging

10.1016/j.ymthe.2006.08.008 · 2006 · External reference

Oncolytic virus therapy of multiple tumours in the brain requires suppression of innate and elicited antiviral responses

10.1038/11320 · 1999 · External reference

Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis

10.1038/sj.gt.3302143 · 2004 · External reference

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

10.1073/pnas.0605496103 · 2006 · External reference

New biological therapeutics: competitors or collaborators of viral therapy for human cancers

2005 · External reference

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumourally to patients with recurrent head and neck cancer

2000 · External reference

China approves world's first oncolytic virus therapy for cancer treatment

10.1093/jnci/djj111 · 2006 · External reference

A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies

2007 · External reference

MTH-68/H oncolytic viral treatment in human high-grade gliomas

10.1023/b:neon.0000021735.85511.05 · 2004 · External reference

Unresolved reference

External reference

Future prospects for oncolytic therapy

10.1038/sj.onc.1209064 · 2005 · External reference

a controlled trial of intratumoural ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

10.1038/78638 · 2000 · External reference

Regulatory aspects of oncolytic virus products

10.2174/156800907780058790 · 2007 · External reference

Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses

10.1038/sj.onc.1209045 · 2005 · External reference

Striking out at disseminated metastases: the systemic delivery of oncolytic viruses

2006 · External reference

Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney

10.1089/10430340050015806 · 2000 · External reference

Pre-existent adenovirus antibody inhibits systemic toxicity and antitumour activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy

10.1089/10430340050083289 · 2000 · External reference

Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies

10.1016/j.ymthe.2004.08.015 · 2004 · External reference

Complement depletion facilitates the infection of multiple brain tumours by an intravascular, replication-conditional herpes simplex virus mutant

10.1128/jvi.74.10.4765-4775.2000 · 2000 · External reference

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery

10.1016/j.ymthe.2006.01.003 · 2006 · External reference

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer

10.1038/sj.mt.6300098 · 2007 · External reference

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity

10.1038/sj.mt.6300039 · 2007 · External reference

Oncolytic adenoviruses - selective retargeting to tumour cells

10.1038/sj.onc.1209044 · 2005 · External reference

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions

10.1158/0008-5472.can-06-2871 · 2007 · External reference

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumour in an ovarian cancer xenograft model

10.1038/sj.cgt.7700948 · 2006 · External reference

Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides

10.1038/nm0502-527 · 2002 · External reference

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene

10.1182/blood-2007-01-065573 · 2007 · External reference

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

10.1182/blood-2003-07-2233 · 2004 · External reference

Virus evolution

2001 · External reference

Fighting cancer with oncolytic viruses

10.1136/bmj.332.7534.170 · 2006 · External reference

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

10.1038/sj.cgt.7700539 · 2002 · External reference

Synergistic antitumour effects of immune cell-viral biotherapy

10.1126/science.1121411 · 2006 · External reference

Adaptability costs in immune escape variants of vesicular stomatitis virus

10.1016/j.virusres.2004.06.007 · 2005 · External reference

Unresolved reference

External reference

Morphogens, morphostats, microarchitecture and malignancy

10.1038/nrc2146 · 2007 · External reference

Targeting the mechanisms of tumoural immune tolerance with small-molecule inhibitors

10.1038/nrc1929 · 2006 · External reference

Drug penetration in solid tumours

10.1038/nrc1893 · 2006 · External reference

Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumours in vivo

2001 · External reference

The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion

10.1038/bjc.1997.53 · 1997 · External reference

Microenvironmental and cellular consequences of altered blood flow in tumours

10.1259/bjr/12913493 · 2003 · External reference

Targeted inflammation during oncolytic virus therapy severely compromises tumour blood flow

10.1038/sj.mt.6300215 · 2007 · External reference

Targeted therapy for cancer stem cells: the patched pathway and ABC transporters

10.1038/sj.onc.1210200 · 2007 · External reference

Molecular targets in radiation oncology

10.1038/sj.onc.1206662 · 2003 · External reference

Viruses: tools for tumour target discovery, and agents for oncolytic therapies—an introduction

10.1038/sj.onc.1209035 · 2005 · External reference

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

2001 · External reference

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

10.1038/sj.cgt.7700585 · 2003 · External reference

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints

2002 · External reference

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

10.1038/sj.gt.3301512 · 2001 · External reference

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

10.1038/sj.gt.3302436 · 2005 · External reference

Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

10.1038/sj.cgt.7700431 · 2002 · External reference

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer

10.1200/jco.20.6.1562 · 2002 · External reference

Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus

10.1038/sj.cgt.7700455 · 2002 · External reference

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

10.1038/sj.gt.3301398 · 2001 · External reference

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumourally to patients with recurrent head and neck cancer

2000 · External reference

Selective replication and oncolysis in p53 mutant tumours with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial

2000 · External reference

Phase II trial of intratumoural administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

10.1200/jco.2001.19.2.289 · 2001 · External reference

[Safety of an E1B deleted adenovirus administered intratumourally to patients with cancer]

2003 · External reference

Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer

2002 · External reference

[Phase II clinical study of intratumoural H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer]

2003 · External reference

[Phase III randomized clinical trial of intratumoural injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]

2004 · External reference

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoural region of recurrent malignant gliomas, in the adjuvant setting

10.1016/j.ymthe.2004.07.021 · 2004 · External reference

The dl1520 virus is found preferentially in tumour tissue after direct intratumoural injection in oral carcinoma

10.1158/1078-0432.ccr-03-0443 · 2004 · External reference

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumours

10.1089/10430340150218369 · 2001 · External reference

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer

10.1200/jco.2003.09.114 · 2003 · External reference

A phase I/II trial of intratumoural endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma

2003 · External reference

Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumour and stromal cells from a patient with gall bladder carcinoma implants

2003 · External reference

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

10.1038/sj.gt.3302289 · 2004 · External reference

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

10.1038/sj.gt.3301205 · 2000 · External reference

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

10.1016/s0140-6736(00)04048-4 · 2001 · External reference

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

10.1038/sj.gt.3301664 · 2002 · External reference

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

10.1023/b:neon.0000003651.97832.6c · 2003 · External reference

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer

10.1016/s0022-5347(05)65755-2 · 2001 · External reference

Intratumoural recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

10.1038/sj.cgt.7700066 · 1999 · External reference

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation

10.1038/sj.cgt.7700133 · 2000 · External reference

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

10.1016/j.ymthe.2005.08.016 · 2006 · External reference

Overview of phase I studies of intravenous administration of PV701, an oncolytic virus

2003 · External reference

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

10.1200/jco.2002.08.042 · 2002 · External reference

Unresolved reference

External reference

Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus

10.1002/1097-0142(195209)5:5<1025::aid-cncr2820050518>3.0.co;2-q · 1952 · External reference

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumour cells

10.1128/jvi.01408-06 · 2007 · External reference

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor

10.1073/pnas.0509341103 · 2006 · External reference

Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumours

10.1158/1078-0432.ccr-07-1330 · 2008 · External reference

Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants

10.1002/ijc.20078 · 2004 · External reference

Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results

10.1038/sj.cgt.7700851 · 2005 · External reference